Tower Research Capital LLC (TRC) - DENALI THERAPEUTICS INC ownership

DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 4 filers reported holding DENALI THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
Tower Research Capital LLC (TRC) ownership history of DENALI THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$35,236
-80.1%
1,708
-71.5%
0.00%
-83.3%
Q2 2023$176,764
+192034.8%
5,990
+49.6%
0.01%
+100.0%
Q1 2023$92
+109.1%
4,005
+157.7%
0.00%
+50.0%
Q4 2022$44
-100.0%
1,554
-89.1%
0.00%
-71.4%
Q3 2022$437,000
+41.4%
14,216
+35.2%
0.01%0.0%
Q2 2022$309,000
+354.4%
10,516
+401.5%
0.01%
+600.0%
Q1 2022$68,000
-79.3%
2,097
-71.4%
0.00%
-83.3%
Q4 2021$328,000
+20.1%
7,339
+35.5%
0.01%
-14.3%
Q3 2021$273,000
-23.1%
5,415
+19.6%
0.01%
-22.2%
Q2 2021$355,000
-18.8%
4,527
-40.9%
0.01%
+28.6%
Q1 2021$437,000
+29.3%
7,662
+89.8%
0.01%
-30.0%
Q4 2020$338,000
+307.2%
4,037
+75.1%
0.01%
+900.0%
Q3 2020$83,000
-64.2%
2,306
-75.9%
0.00%
-90.0%
Q2 2020$232,000
+625.0%
9,581
+357.3%
0.01%
+400.0%
Q3 2019$32,000
+1500.0%
2,095
+1721.7%
0.00%
Q2 2019$2,000
-89.5%
115
-86.1%
0.00%
-100.0%
Q1 2019$19,000
+850.0%
828
+673.8%
0.00%
Q4 2018$2,000
-96.4%
107
-97.1%
0.00%
-100.0%
Q2 2018$56,0003,6680.00%
Other shareholders
DENALI THERAPEUTICS INC shareholders Q4 2023
NameSharesValueWeighting ↓
Crestline Management, LP 7,460,732$219,569,00028.65%
ARCH Venture Management, LLC 5,168,749$152,116,00018.54%
Casdin Capital, LLC 1,500,000$44,145,0003.73%
Flagship Pioneering Inc. 2,619,968$77,106,0002.90%
Yiheng Capital Management, L.P. 1,014,684$29,862,0001.71%
SECTORAL ASSET MANAGEMENT INC 202,100$5,948,0001.20%
GILDER GAGNON HOWE & CO LLC 1,956,820$57,589,0001.03%
Artal Group S.A. 600,000$17,658,0000.94%
Temasek Holdings (Private) Ltd 5,369,487$158,024,0020.87%
BRANDYWINE MANAGERS, LLC 9,601$283,0000.69%
View complete list of DENALI THERAPEUTICS INC shareholders